Ulixertinib is an inhibitor of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival.

1956366-10-1

C21H23Cl3N4O2

469.79

BVD523;VRT752271;BVD-523;VRT 752271;Ulixertinib HCl;BVD 523;Ulixertinib hydrochloride

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years